{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:55:56Z","timestamp":1793094956354,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"The Netherlands Organisation for Health Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Partnership for Personalised Medicine - EP PerMed"},{"name":"Foundation for Science and Technology"},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Influenza-associated pulmonary aspergillosis (IAPA) is a frequent and often fatal complication of severe influenza in critically ill patients. Despite increased recognition, its real global burden and optimal prevention strategies remain uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A structured literature review of studies published between January 2000 and June 2025 was conducted to summarize IAPA incidence, fatality rate and study heterogeneity. Continuous variables were summarized as trimmed medians (central 80%) with bootstrapped 95% confidence intervals. Between-study heterogeneity and methodological diversity were quantified using the I\u00b2 and Shannon diversity indices. Non-parametric tests assessed subgroup differences and correlations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty-three studies (527,475 patients) were included. The trimmed median IAPA incidence was 14.55% (95% CI, 11.16\u201319.21), and the case-fatality rate was 50.00% (95% CI, 42.86\u201358.54). IAPA occurred more frequently in ICU-only cohorts (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011) and was associated with higher mortality (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.025). Heterogeneity across studies was substantial (I\u00b2 = 96.1% for incidence; 79.6% for fatality), reflecting differences in diagnostic definitions and patient selection. Universal antifungal prophylaxis, including posaconazole, did not confer a significant survival benefit.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IAPA affects approximately one in six critically ill influenza patients and carries a mortality of around 50%. Rather than a one-size-fits-all approach, future studies are needed to evaluate more individualized therapy concepts that account for patient- and disease-specific factors and may improve overall outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13054-026-05975-1","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:36:14Z","timestamp":1774517774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Incidence and outcomes of influenza-associated pulmonary aspergillosis and the role of antifungal prophylaxis: a structured literature review"],"prefix":"10.1186","volume":"30","author":[{"given":"Sarah","family":"Sedik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Felber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schellongowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut J.F.","family":"Salzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romuald","family":"Bellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Muhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Auer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Krippl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Zajic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Watzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Mesaric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Tinawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Dichtl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Wolfgruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhra","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Prattes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Feys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L.","family":"van de Veerdonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannes","family":"Heylen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostinho","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Augusto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hoenigl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"3","key":"5975_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw171","volume":"3","author":"NF Crum-Cianflone","year":"2016","unstructured":"Crum-Cianflone NF. Invasive aspergillosis associated with severe influenza infections. Open Forum Infect Dis. 2016;3(3):ofw171.","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"5975_CR2","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1007\/s00134-020-06091-6","volume":"46","author":"PE Verweij","year":"2020","unstructured":"Verweij PE, Rijnders BJA, Bruggemann RJM, Azoulay E, Bassetti M, Blot S, et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med. 2020;46(8):1524\u201335.","journal-title":"Intensive Care Med"},{"issue":"11","key":"5975_CR3","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/s00134-012-2673-2","volume":"38","author":"J Wauters","year":"2012","unstructured":"Wauters J, Baar I, Meersseman P, Meersseman W, Dams K, De Paep R, et al. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Med. 2012;38(11):1761\u20138.","journal-title":"Intensive Care Med"},{"key":"5975_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00151-6","author":"S Feys","year":"2024","unstructured":"Feys S, Carvalho A, Clancy CJ, Gangneux J-P, Hoenigl M, Lagrou K, et al. Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients. Lancet Respir Med. 2024. https:\/\/doi.org\/10.1016\/S2213-2600(24)00151-6.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"5975_CR5","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","volume":"6","author":"A Schauwvlieghe","year":"2018","unstructured":"Schauwvlieghe A, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6(10):782\u201392.","journal-title":"Lancet Respir Med"},{"key":"5975_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jof7110922","author":"CM Chao","year":"2021","unstructured":"Chao CM, Lai CC, Ou HF, Ho CH, Chan KS, Yang CC, et al. The impacts of aspergillosis on outcome, burden and risks for mortality in influenza patients with critical illness. J Fungi. 2021. https:\/\/doi.org\/10.3390\/jof7110922.","journal-title":"J Fungi"},{"issue":"4","key":"5975_CR7","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1164\/rccm.201612-2540LE","volume":"196","author":"FL van de Veerdonk","year":"2017","unstructured":"van de Veerdonk FL, Kolwijck E, Lestrade PP, Hodiamont CJ, Rijnders BJ, van Paassen J, et al. Influenza-associated aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2017;196(4):524\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"5975_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00134-021-06431-0","volume":"47","author":"L Vanderbeke","year":"2021","unstructured":"Vanderbeke L, Janssen NAF, Bergmans D, Bourgeois M, Buil JB, Debaveye Y, et al. Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. Intensive Care Med. 2021;47(6):674\u201386.","journal-title":"Intensive Care Med"},{"key":"5975_CR9","doi-asserted-by":"crossref","unstructured":"Hatzl S, Kriegl L, Geiger C, Wilhelmer C, Reisinger AC, Keldorfer M et al. Empirical antifungal treatment of critically ill patients with influenza-associated acute respiratory distress syndrome: A propensity score weighted observational study. Clin Infect Dis. 2025.","DOI":"10.1093\/cid\/ciaf507"},{"issue":"3","key":"5975_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-024-00852-3","volume":"189","author":"M Hoenigl","year":"2024","unstructured":"Hoenigl M, Enoch DA, Wichmann D, Wyncoll D, Cortegiani A. Exploring European consensus about the remaining treatment challenges and subsequent opportunities to improve the management of invasive fungal infection (IFI) in the intensive care unit. Mycopathologia. 2024;189(3):41.","journal-title":"Mycopathologia"},{"key":"5975_CR11","doi-asserted-by":"crossref","unstructured":"Manchon R, Feys S, Hoenigl M, van de Veerdonk FL, Lanternier F, Wauters J et al. Aspergillus and host-pathogen interaction: focus on treatment-relevant aspects. Clin Microbiol Infect. 2025.","DOI":"10.1016\/j.cmi.2025.08.030"},{"issue":"0","key":"5975_CR12","first-page":"e00074","volume":"0","author":"M Hoenigl","year":"2024","unstructured":"Hoenigl M, Arastehfar A, Arendrup Maiken C, Br\u00fcggemann R, Carvalho A, Chiller T, et al. Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease. Clin Microbiol Rev. 2024;0(0):e00074\u201323.","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"5975_CR13","doi-asserted-by":"publisher","first-page":"e0198223","DOI":"10.1128\/mbio.01982-23","volume":"15","author":"SM Gon\u00e7alves","year":"2024","unstructured":"Gon\u00e7alves SM, Pereira I, Feys S, Cunha C, Chamilos G, Hoenigl M, et al. Integrating genetic and immune factors to uncover pathogenetic mechanisms of viral-associated pulmonary aspergillosis. mBio. 2024;15(6):e0198223.","journal-title":"mBio"},{"issue":"3","key":"5975_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.chest.2023.09.019","volume":"165","author":"LY Lu","year":"2024","unstructured":"Lu LY, Lee HM, Burke A, Li Bassi G, Torres A, Fraser JF, et al. Prevalence, Risk Factors, Clinical Features, and Outcome of Influenza-Associated Pulmonary Aspergillosis in Critically Ill Patients: A Systematic Review and Meta-Analysis. Chest. 2024;165(3):540\u201358.","journal-title":"Chest"},{"issue":"7","key":"5975_CR15","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1093\/cid\/ciaa010","volume":"71","author":"BJA Rijnders","year":"2020","unstructured":"Rijnders BJA, Schauwvlieghe A, Wauters J. Influenza-associated pulmonary aspergillosis: a local or global lethal combination? Clin Infect Dis. 2020;71(7):1764\u20137.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"5975_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-021-00923-4","volume":"11","author":"G Montrucchio","year":"2021","unstructured":"Montrucchio G, Lupia T, Lombardo D, Stroffolini G, Corcione S, De Rosa FG, et al. Risk factors for invasive aspergillosis in ICU patients with COVID-19: current insights and new key elements. Ann Intensive Care. 2021;11(1):136.","journal-title":"Ann Intensive Care"},{"key":"5975_CR17","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0114-2022","author":"F Lamoth","year":"2022","unstructured":"Lamoth F, Calandra T. Pulmonary aspergillosis: diagnosis and treatment. Eur Respir Rev. 2022. https:\/\/doi.org\/10.1183\/16000617.0114-2022.","journal-title":"Eur Respir Rev"},{"issue":"11","key":"5975_CR18","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/apm.13316","volume":"131","author":"S Gaffney","year":"2023","unstructured":"Gaffney S, Kelly DM, Rameli PM, Kelleher E, Martin-Loeches I. Invasive pulmonary aspergillosis in the intensive care unit: current challenges and best practices. APMIS. 2023;131(11):654\u201367.","journal-title":"APMIS"},{"issue":"11","key":"5975_CR19","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.jclinepi.2014.05.008","volume":"67","author":"WA van Enst","year":"2014","unstructured":"van Enst WA, Scholten RJ, Whiting P, Zwinderman AH, Hooft L. Meta-epidemiologic analysis indicates that MEDLINE searches are sufficient for diagnostic test accuracy systematic reviews. J Clin Epidemiol. 2014;67(11):1192\u20139.","journal-title":"J Clin Epidemiol"},{"key":"5975_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jpsychores.2016.06.002","volume":"87","author":"DB Rice","year":"2016","unstructured":"Rice DB, Kloda LA, Levis B, Qi B, Kingsland E, Thombs BD. Are MEDLINE searches sufficient for systematic reviews and meta-analyses of the diagnostic accuracy of depression screening tools? A review of meta-analyses. J Psychosom Res. 2016;87:7\u201313.","journal-title":"J Psychosom Res"},{"key":"5975_CR21","doi-asserted-by":"crossref","unstructured":"Janssen NAF, Vanderbeke L, Jacobs C, Feys S, van Dijk K, van der Spoel JI et al. Influenza-associated invasive aspergillosis in the ICU: a prospective, multicentre cohort study. Crit Care. 2025.","DOI":"10.1186\/s13054-025-05771-3"},{"issue":"6","key":"5975_CR22","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367\u201376.","journal-title":"Clin Infect Dis"},{"key":"5975_CR23","unstructured":"Organization WH. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). Volume 2: Alphabetical Index. Geneva: World Health Organization; 2019. Available from: https:\/\/icd.who.int\/browse10\/Content\/statichtml\/ICD10Volume2_en_2019.pdf"},{"key":"5975_CR24","unstructured":"Statement PPRISMA, London C. PRISMA Group; 2020 [Available from: https:\/\/www.prisma-statement.org\/prisma-2020-checklist"},{"issue":"2","key":"5975_CR25","first-page":"16","volume":"8","author":"SA Ali","year":"2022","unstructured":"Ali SA, Jabeen K, Farooqi J, Niamatullah H, Siddiqui AF, Awan S, et al. Invasive pulmonary aspergillosis in critically ill patients with pneumonia due to COVID-19, influenza, and community-acquired pneumonia: A prospective observational study. Curr Med Mycol. 2022;8(2):16\u201324.","journal-title":"Curr Med Mycol"},{"key":"5975_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9100644","author":"V Bellelli","year":"2020","unstructured":"Bellelli V, Siccardi G, Conte L, Celani L, Congeduti E, Borrazzo C, et al. Preliminary attempt to predict risk of invasive pulmonary aspergillosis in patients with influenza: decision trees may help? Antibiotics (Basel). 2020. https:\/\/doi.org\/10.3390\/antibiotics9100644.","journal-title":"Antibiotics (Basel)"},{"key":"5975_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jcrc.2018.11.013","volume":"50","author":"MC Beumer","year":"2019","unstructured":"Beumer MC, Koch RM, van Beuningen D, OudeLashof AM, van de Veerdonk FL, Kolwijck E, et al. Influenza virus and factors that are associated with ICU admission, pulmonary co-infections and ICU mortality. J Crit Care. 2019;50:59\u201365.","journal-title":"J Crit Care"},{"key":"5975_CR28","doi-asserted-by":"crossref","unstructured":"Boyd S, Sheng Loh K, Lynch J, Alrashed D, Muzzammil S, Marsh H et al. Elevated Rates of Ventilator-Associated Pneumonia and COVID-19 Associated Pulmonary Aspergillosis in Critically Ill Patients with SARS-CoV2 Infection in the Second Wave: A Retrospective Chart Review. Antibiotics (Basel). 2022;11(5).","DOI":"10.3390\/antibiotics11050632"},{"issue":"1","key":"5975_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-01257-w","volume":"20","author":"L Chen","year":"2020","unstructured":"Chen L, Han X, Li Y, Zhang C, Xing X. Invasive pulmonary aspergillosis in immunocompetent patients hospitalised with influenza A-related pneumonia: a multicenter retrospective study. BMC Pulm Med. 2020;20(1):239.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"5975_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2155584","volume":"12","author":"YJ Chen","year":"2023","unstructured":"Chen YJ, Lin IF, Chuang JH, Huang HL, Chan TC. Influenza vaccination is associated with a reduced risk of invasive aspergillosis in high-risk individuals in Taiwan: a population-based cohort study. Emerg Microbes Infect. 2023;12(1):2155584.","journal-title":"Emerg Microbes Infect"},{"key":"5975_CR31","doi-asserted-by":"publisher","first-page":"1195048","DOI":"10.3389\/fpubh.2023.1195048","volume":"11","author":"Z Chen","year":"2023","unstructured":"Chen Z, Zhan Q, Huang L, Wang C. Coinfection and superinfection in ICU critically ill patients with severe COVID-19 pneumonia and influenza pneumonia: are the pictures different? Front Public Health. 2023;11:1195048.","journal-title":"Front Public Health"},{"issue":"8","key":"5975_CR32","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.medin.2021.12.005","volume":"46","author":"L Claverias","year":"2022","unstructured":"Claverias L, Daniel X, Martin-Loeches I, Vidal-Cortez P, Gomez-Bertomeu F, Trefler S, et al. Impact of Aspergillus spp. isolation in the first 24 hours of admission in critically ill patients with severe influenza virus pneumonia. Med Intensiva. 2022;46(8):426\u201335.","journal-title":"Med Intensiva"},{"key":"5975_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.602732","volume":"7","author":"Y Duan","year":"2020","unstructured":"Duan Y, Ou X, Chen Y, Liang B, Ou X. Severe influenza with invasive pulmonary aspergillosis in immunocompetent hosts: a retrospective cohort study. Front Med (Lausanne). 2020;7:602732.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"5975_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-023-01196-9","volume":"13","author":"G Dumas","year":"2023","unstructured":"Dumas G, Bertrand M, Lemiale V, Canet E, Barbier F, Kouatchet A, et al. Prognosis of critically ill immunocompromised patients with virus-detected acute respiratory failure. Ann Intensive Care. 2023;13(1):101.","journal-title":"Ann Intensive Care"},{"issue":"10","key":"5975_CR35","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1164\/rccm.202401-0145OC","volume":"210","author":"S Feys","year":"2024","unstructured":"Feys S, Cardinali-Benigni M, Lauwers HM, Jacobs C, Stevaert A, Goncalves SM, et al. Profiling bacteria in the lungs of patients with severe influenza versus COVID-19 with or without aspergillosis. Am J Respir Crit Care Med. 2024;210(10):1230\u201342.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"5975_CR36","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S2213-2600(22)00259-4","volume":"10","author":"S Feys","year":"2022","unstructured":"Feys S, Goncalves SM, Khan M, Choi S, Boeckx B, Chatelain D, et al. Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study. Lancet Respir Med. 2022;10(12):1147\u201359.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"5975_CR37","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jinf.2020.07.036","volume":"81","author":"L Huang","year":"2020","unstructured":"Huang L, Zhai T, Hua L, Zhan Q. Early identification of patients with severe influenza-associated aspergillosis (IAA) in the intensive care unit\u2013an IAA prediction score system (Asper-PreSS). J Infect. 2020;81(4):639\u201346.","journal-title":"J Infect"},{"issue":"9","key":"5975_CR38","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1007\/s10096-021-04228-z","volume":"40","author":"L Huang","year":"2021","unstructured":"Huang L, Zhang Y, Hua L, Zhan Q. Diagnostic value of galactomannan test in non-immunocompromised critically ill patients with influenza-associated aspergillosis: data from three consecutive influenza seasons. Eur J Clin Microbiol Infect Dis. 2021;40(9):1899\u2013907.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"5975_CR39","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/23744235.2023.2273381","volume":"56","author":"A Krifors","year":"2024","unstructured":"Krifors A, Blennow O, Pahlman LI, Gille-Johnson P, Janols H, Lipcsey M, et al. Influenza-associated invasive aspergillosis in patients admitted to the intensive care unit in Sweden: a prospective multicentre cohort study. Infect Dis Lond. 2024;56(2):110\u20135.","journal-title":"Infect Dis Lond"},{"issue":"9","key":"5975_CR40","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jfma.2017.06.002","volume":"116","author":"YH Ku","year":"2017","unstructured":"Ku YH, Chan KS, Yang CC, Tan CK, Chuang YC, Yu WL. Higher mortality of severe influenza patients with probable aspergillosis than those with and without other coinfections. J Formos Med Assoc. 2017;116(9):660\u201370.","journal-title":"J Formos Med Assoc"},{"issue":"2","key":"5975_CR41","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jmii.2021.03.005","volume":"55","author":"CW Kuo","year":"2022","unstructured":"Kuo CW, Wang SY, Tsai HP, Su PL, Cia CT, Lai CH, et al. Invasive pulmonary aspergillosis is associated with cytomegalovirus viremia in critically ill patients - a retrospective cohort study. J Microbiol Immunol Infect. 2022;55(2):291\u20139.","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"5975_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s41479-024-00129-9","volume":"16","author":"WC Lee","year":"2024","unstructured":"Lee WC, Chang CC, Ho MC, Lin CM, Leu SW, Lin CK, et al. Invasive pulmonary aspergillosis among patients with severe community-acquired pneumonia and influenza in ICUs: a retrospective cohort study. Pneumonia. 2024;16(1):10.","journal-title":"Pneumonia"},{"issue":"1","key":"5975_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06437-5","volume":"21","author":"L Li","year":"2021","unstructured":"Li L, Hsu SH, Wang C, Li B, Sun L, Shi J, et al. Characteristics of viral pneumonia in non-HIV immunocompromised and immunocompetent patients: a retrospective cohort study. BMC Infect Dis. 2021;21(1):767.","journal-title":"BMC Infect Dis"},{"key":"5975_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1303456","volume":"13","author":"X Li","year":"2023","unstructured":"Li X, Liu Y, Li M, Bian J, Song D, Liu C. Epidemiological investigation of lower respiratory tract infections during influenza A (H1N1) pdm09 virus pandemic based on targeted next-generation sequencing. Front Cell Infect Microbiol. 2023;13:1303456.","journal-title":"Front Cell Infect Microbiol"},{"key":"5975_CR45","doi-asserted-by":"crossref","unstructured":"Liu JW, Ku YH, Chao CM, Ou HF, Ho CH, Chan KS et al. Epidemiological Correlation of Pulmonary Aspergillus Infections with Ambient Pollutions and Influenza A (H1N1) in Southern Taiwan. J Fungi (Basel). 2021;7(3).","DOI":"10.3390\/jof7030227"},{"issue":"30","key":"5975_CR46","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026434","volume":"100","author":"Y Liu","year":"2021","unstructured":"Liu Y, Xie ZZ, Wang X, Zhu ZH, Yang C. Clinical study of invasive pulmonary aspergillosis following influenza A H1N1. Medicine (Baltimore). 2021;100(30):e26434.","journal-title":"Medicine (Baltimore)"},{"key":"5975_CR47","doi-asserted-by":"crossref","unstructured":"Marcoux D, Etienne I, Van Muylem A, Bogossian EG, Yin N, Taccone FS et al. A Retrospective, Monocentric Study Comparing Co and Secondary Infections in Critically Ill COVID-19 and Influenza Patients. Antibiot (Basel). 2022;11(6).","DOI":"10.3390\/antibiotics11060704"},{"issue":"5","key":"5975_CR48","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1164\/rccm.201910-1931OC","volume":"202","author":"R Nyga","year":"2020","unstructured":"Nyga R, Maizel J, Nseir S, Chouaki T, Milic I, Roger PA, et al. Invasive Tracheobronchial Aspergillosis in Critically Ill Patients with Severe Influenza. A Clinical Trial. Am J Respir Crit Care Med. 2020;202(5):708\u201316.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"5975_CR49","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s15010-021-01624-7","volume":"49","author":"A Oliva","year":"2021","unstructured":"Oliva A, Ceccarelli G, Borrazzo C, Ridolfi M, Alessandri GDE. Comparison of clinical features and outcomes in COVID-19 and influenza pneumonia patients requiring intensive care unit admission. Infection. 2021;49(5):965\u201375.","journal-title":"Infection"},{"key":"5975_CR50","doi-asserted-by":"crossref","unstructured":"Reizine F, Pinceaux K, Lederlin M, Autier B, Guegan H, Gacouin A et al. Influenza- and COVID-19-Associated Pulmonary Aspergillosis: Are the Pictures Different? J Fungi (Basel). 2021;7(5).","DOI":"10.3390\/jof7050388"},{"issue":"7","key":"5975_CR51","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s10096-018-3241-7","volume":"37","author":"I Rodriguez-Goncer","year":"2018","unstructured":"Rodriguez-Goncer I, Thomas S, Foden P, Richardson MD, Ashworth A, Barker J, et al. Invasive pulmonary aspergillosis is associated with adverse clinical outcomes in critically ill patients receiving veno-venous extracorporeal membrane oxygenation. Eur J Clin Microbiol Infect Dis. 2018;37(7):1251\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"5975_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03874-1","volume":"26","author":"A Rouze","year":"2022","unstructured":"Rouze A, Lemaitre E, Martin-Loeches I, Povoa P, Diaz E, Nyga R, et al. Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study. Crit Care. 2022;26(1):11.","journal-title":"Crit Care"},{"issue":"9","key":"5975_CR53","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1017\/ice.2020.460","volume":"42","author":"C Sarrazyn","year":"2021","unstructured":"Sarrazyn C, Dhaese S, Demey B, Vandecasteele S, Reynders M, Van Praet JT. Incidence, risk factors, timing, and outcome of influenza versus COVID-19-associated putative invasive aspergillosis. Infect Control Hosp Epidemiol. 2021;42(9):1149\u201350.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"10","key":"5975_CR54","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","volume":"6","author":"A Schauwvlieghe","year":"2018","unstructured":"Schauwvlieghe A, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6(10):782\u201392.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"5975_CR55","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/cid\/ciaa007","volume":"71","author":"IS Schwartz","year":"2020","unstructured":"Schwartz IS, Friedman DZP, Zapernick L, Dingle TC, Lee N, Sligl W, et al. High rates of influenza-associated invasive pulmonary aspergillosis may not be universal: a retrospective cohort study from Alberta, Canada. Clin Infect Dis. 2020;71(7):1760\u20133.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"5975_CR56","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.chest.2020.06.010","volume":"158","author":"A Sharma","year":"2020","unstructured":"Sharma A, Mishra T, Kumar N, Soubani AO. Influenza-associated aspergillosis: nationwide trends, predictors and outcomes from 2005 to 2014. Chest. 2020;158(5):1857\u201366.","journal-title":"Chest"},{"issue":"3","key":"5975_CR57","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s15010-021-01743-1","volume":"50","author":"S Studer","year":"2022","unstructured":"Studer S, Rassouli F, Waldeck F, Brutsche MH, Baty F, Albrich WC. No evidence of harmful effects of steroids in severe exacerbations of COPD associated with influenza. Infection. 2022;50(3):699\u2013707.","journal-title":"Infection"},{"issue":"3","key":"5975_CR58","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab091","volume":"8","author":"M Toda","year":"2021","unstructured":"Toda M, Benedict K, Jackson BR. Invasive aspergillosis after influenza and other viral respiratory infections among intensive care unit patients in a commercially insured population in the United States, 2013\u20132018. Open Forum Infect Dis. 2021;8(3):ofab091.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"5975_CR59","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1164\/rccm.201903-0587LE","volume":"200","author":"K van de Groep","year":"2019","unstructured":"van de Groep K, Verboom DM, van de Veerdonk FL, Haas PA, van der Poll T, Schultz MJ, et al. Detection of invasive aspergillosis in critically ill patients with influenza: the role of plasma galactomannan. Am J Respir Crit Care Med. 2019;200(5):636\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"5975_CR60","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1164\/rccm.201612-2540LE","volume":"196","author":"FL van de Veerdonk","year":"2017","unstructured":"van de Veerdonk FL, Kolwijck E, Lestrade PP, Hodiamont CJ, Rijnders BJ, van Paassen J, et al. Influenza-associated aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2017;196(4):524\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"5975_CR61","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1164\/rccm.202208-1570OC","volume":"208","author":"L Vanderbeke","year":"2023","unstructured":"Vanderbeke L, Jacobs C, Feys S, Resendiz-Sharpe A, Debaveye Y, Hermans G, et al. A pathology-based case series of influenza- and COVID-19-associated pulmonary aspergillosis: the proof is in the tissue. Am J Respir Crit Care Med. 2023;208(3):301\u201311.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"5975_CR62","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1017\/S0950268811002603","volume":"140","author":"JJ Vehreschild","year":"2012","unstructured":"Vehreschild JJ, Brockelmann PJ, Bangard C, Verheyen J, Vehreschild MJ, Michels G, et al. Pandemic 2009 influenza A(H1N1) virus infection coinciding with invasive pulmonary aspergillosis in neutropenic patients. Epidemiol Infect. 2012;140(10):1848\u201352.","journal-title":"Epidemiol Infect"},{"issue":"10","key":"5975_CR63","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s10096-020-03923-7","volume":"39","author":"F Waldeck","year":"2020","unstructured":"Waldeck F, Boroli F, Suh N, Wendel Garcia PD, Flury D, Notter J, et al. Influenza-associated aspergillosis in critically-ill patients-a retrospective bicentric cohort study. Eur J Clin Microbiol Infect Dis. 2020;39(10):1915\u201323.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"5975_CR64","doi-asserted-by":"publisher","first-page":"e13059","DOI":"10.1111\/irv.13059","volume":"17","author":"F Waldeck","year":"2023","unstructured":"Waldeck F, Boroli F, Zingg S, Walti LN, Wendel-Garcia PD, Conen A, et al. Higher risk for influenza-associated pulmonary aspergillosis (IAPA) in asthmatic patients: A Swiss multicenter cohort study on IAPA in critically ill influenza patients. Influenza Other Respir Viruses. 2023;17(1):e13059.","journal-title":"Influenza Other Respir Viruses"},{"key":"5975_CR65","doi-asserted-by":"crossref","unstructured":"Wu CJ, Cia CT, Wang HC, Chen CW, Lin WC, Lee JC et al. Clinical and Microbiological Characteristics of Culture-Positive, Influenza-Associated Pulmonary Aspergillosis: A Single-Center Study in Southern Taiwan, 2016\u20132019. J Fungi (Basel). 2022;8(1).","DOI":"10.3390\/jof8010049"},{"issue":"4","key":"5975_CR66","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10096-024-04772-4","volume":"43","author":"J Zhao","year":"2024","unstructured":"Zhao J, Zhuo X, Pu D, Fan G, Lu B, Cao B. Comparison of influenza- and COVID-19-associated pulmonary aspergillosis in China. Eur J Clin Microbiol Infect Dis. 2024;43(4):683\u201392.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl 2","key":"5975_CR67","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1093\/infdis\/jiz682","volume":"221","author":"P Zou","year":"2020","unstructured":"Zou P, Wang C, Zheng S, Guo F, Yang L, Zhang Y, et al. Invasive Pulmonary Aspergillosis in Adults With Avian Influenza A (H7N9) Pneumonia in China: A Retrospective Study. J Infect Dis. 2020;221(Suppl 2):S193\u20137.","journal-title":"J Infect Dis"},{"issue":"5","key":"5975_CR68","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13309","volume":"22","author":"SR Jaiswal","year":"2020","unstructured":"Jaiswal SR, Bhagwati G, Soni M, Thatai A, Aiyer H, Chakrabarti S. Prophylactic oseltamivir during major seasonal influenza H1N1 outbreak might reduce both H1N1 and associated pulmonary aspergillosis in children undergoing haploidentical transplantation. Transpl Infect Dis. 2020;22(5):e13309.","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"5975_CR69","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1086\/505122","volume":"43","author":"J Guarner","year":"2006","unstructured":"Guarner J, Paddock CD, Shieh WJ, Packard MM, Patel M, Montague JL, et al. Histopathologic and immunohistochemical features of fatal influenza virus infection in children during the 2003\u20132004 season. Clin Infect Dis. 2006;43(2):132\u201340.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"5975_CR70","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/crj.12995","volume":"13","author":"L Huang","year":"2019","unstructured":"Huang L, Zhang N, Huang X, Xiong S, Feng Y, Zhang Y, et al. Invasive pulmonary aspergillosis in patients with influenza infection: a retrospective study and review of the literature. Clin Respir J. 2019;13(4):202\u201311.","journal-title":"Clin Respir J"},{"issue":"6","key":"5975_CR71","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1097\/CCM.0000000000004861","volume":"49","author":"A Coste","year":"2021","unstructured":"Coste A, Frerou A, Raute A, Couturaud F, Morin J, Egreteau PY, et al. The Extent of Aspergillosis in Critically Ill Patients With Severe Influenza Pneumonia: A Multicenter Cohort Study. Crit Care Med. 2021;49(6):934\u201342.","journal-title":"Crit Care Med"},{"issue":"12","key":"5975_CR72","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813\u201321.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"5975_CR73","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1164\/rccm.201111-1978OC","volume":"186","author":"SI Blot","year":"2012","unstructured":"Blot SI, Taccone FS, Van den Abeele AM, Bulpa P, Meersseman W, Brusselaers N, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186(1):56\u201364.","journal-title":"Am J Respir Crit Care Med"},{"key":"5975_CR74","doi-asserted-by":"crossref","unstructured":"Bassetti M, Giacobbe DR, Agvald-Ohman C, Akova M, Alastruey-Izquierdo A, Arikan-Akdagli S et al. Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM. Intensive Care Med. 2024.","DOI":"10.1007\/s00134-024-07341-7"},{"issue":"6","key":"5975_CR75","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1164\/rccm.202310-1815VP","volume":"209","author":"S Feys","year":"2024","unstructured":"Feys S, Hoenigl M, Gangneux JP, Verweij PE, Wauters J. Fungal fog in viral storms: necessity for rigor in aspergillosis diagnosis and research. Am J Respir Crit Care Med. 2024;209(6):631\u20133.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"5975_CR76","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s40121-023-00818-w","volume":"12","author":"RT Liu","year":"2023","unstructured":"Liu RT, Chen Y, Li S, Wan XX, Weng L, Peng JM, et al. A comparison of diagnostic criteria for invasive pulmonary aspergillosis in critically ill patients. Infect Dis Ther. 2023;12(6):1641\u201353.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"5975_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-021-00827-3","volume":"11","author":"J Hamam","year":"2021","unstructured":"Hamam J, Navellou J-C, Bellanger A-P, Bretagne S, Winiszewski H, Scherer E, et al. New clinical algorithm including fungal biomarkers to better diagnose probable invasive pulmonary aspergillosis in ICU. Ann Intensive Care. 2021;11(1):41.","journal-title":"Ann Intensive Care"},{"issue":"2","key":"5975_CR78","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00134-022-06958-w","volume":"49","author":"S Feys","year":"2023","unstructured":"Feys S, Heylen J, Carvalho A, Van Weyenbergh J, Wauters J, Gon\u00e7alves SM, et al. A signature of differential gene expression in bronchoalveolar lavage fluid predicts mortality in influenza-associated pulmonary aspergillosis. Intensive Care Med. 2023;49(2):254\u20137.","journal-title":"Intensive Care Med"},{"issue":"8","key":"5975_CR79","doi-asserted-by":"publisher","first-page":"e1008741","DOI":"10.1371\/journal.ppat.1008741","volume":"16","author":"BD Snarr","year":"2020","unstructured":"Snarr BD, St-Pierre G, Ralph B, Lehoux M, Sato Y, Rancourt A, et al. Galectin-3 enhances neutrophil motility and extravasation into the airways during Aspergillus fumigatus infection. PLoS Pathog. 2020;16(8):e1008741.","journal-title":"PLoS Pathog"},{"key":"5975_CR80","doi-asserted-by":"crossref","unstructured":"Rotshenker S. Galectin-3 (MAC-2) controls phagocytosis and macropinocytosis through intracellular and extracellular mechanisms. Front Cell Neurosci. 2022;Volume 16\u20132022.","DOI":"10.3389\/fncel.2022.949079"},{"key":"5975_CR81","unstructured":"Feys SRL, Cato Jacobs SMG, Lauwers HM, Debaveye Y, Hermans G, Meersseman P, Lagrou K, Peetermans M, Van De Veerdonk F, Vandenbriele C. Alexander Wilmer, Cristina Cunha, Joost Wauters, Agostinho Carvalho. Galectin-3 (LGALS3) rs4644 polymorphism predisposes to development of aspergillosis in severe influenza patients. ECCMID 2023: ESCMID Library; 2023."}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-026-05975-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-026-05975-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-026-05975-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:55:21Z","timestamp":1781643321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13054-026-05975-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5975"],"URL":"https:\/\/doi.org\/10.1186\/s13054-026-05975-1","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"P.S. received personal fees from Abbvie, Astro Pharma, Fresenius Medical, Getinge, Gilead, Pfizer, and Roche, his institution received research funding from Astro Pharma, all unrelated to the submitted work. H.J.F.S. received speaker honoraria from AstraZeneca, Bristol-Myers Squibb, and Insmed, all unrelated to the submitted work. K.D. received research funding by Euroimmun, Fujifilm Wako, bioM\u00e9rieux, Quantamatrix, and Zybio, all unrelated to the submitted work. J.P. received research funding from Pfizer and MSD, speaker fees from Pfizer, Gilead Sciences, Associates of Cape Cod, and SOBI, all unrelated to the submitted work. S.F. received travel grants from Pfizer and Gilead, funding for a public doctoral defence from Pfizer, Gilead and Mundipharma, and has received a speaker\u2019s fee from Healtbook Company Ltd. J.W. received research funding from Gilead, MSD and Pfizer, all unrelated to the submitted work and received travel grants and speakers fees from Pfizer, MundiPharma and Gilead. A.C. received speaker fees from Gilead. M.H. received research funding from Gilead, Astellas, Basilea, Elion, MSD, GSK, IMMY, Pulmocide, Shionogi, Melinta, Mundipharma, Scynexis, F2G, ZeptoLifeSciences, and Pfizer, all unrelated to the submitted work. All other authors declare no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}